Lobe Sciences Ltd
Lobe Sciences Ltd., a biopharmaceutical company, engages in the research and development of lipid technology to develop innovative treatments for orphan and rare diseases. It offers Altemia® MF, a medical food designed to manage deficiencies in sickle cel disease. Lobe Sciences Ltd. was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. The … Read more
Lobe Sciences Ltd (LOBEF) - Total Assets
Latest total assets as of November 2025: $7.08 Million USD
Based on the latest financial reports, Lobe Sciences Ltd (LOBEF) holds total assets worth $7.08 Million USD as of November 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lobe Sciences Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Lobe Sciences Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lobe Sciences Ltd - Asset Composition Analysis
Current Asset Composition (August 2025)
Lobe Sciences Ltd's total assets of $7.08 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.1% |
| Accounts Receivable | $47.50K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Lobe Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lobe Sciences Ltd's current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 77.1% of total assets in 2025, down from 97.6% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Lobe Sciences Ltd Competitors by Total Assets
Key competitors of Lobe Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lobe Sciences Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Lobe Sciences Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Lobe Sciences Ltd is currently not profitable relative to its asset base.
Lobe Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.33 | 0.03 | 3.42 |
| Quick Ratio | 2.33 | 0.03 | 3.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.05 Million | $ -2.20 Million | $ 899.93K |
Lobe Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between Lobe Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.51 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 2835.0% |
| Total Assets | $7.59 Million |
| Market Capitalization | $378.13K USD |
Valuation Analysis
Below Book Valuation: The market values Lobe Sciences Ltd's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Lobe Sciences Ltd's assets grew by 2835.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Lobe Sciences Ltd (2017–2025)
The table below shows the annual total assets of Lobe Sciences Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | $7.59 Million | +2835.01% |
| 2024-08-31 | $258.57K | -88.76% |
| 2023-08-31 | $2.30 Million | +31.57% |
| 2022-08-31 | $1.75 Million | -85.55% |
| 2021-08-31 | $12.10 Million | -6.73% |
| 2020-08-31 | $12.97 Million | +92.99% |
| 2019-08-31 | $6.72 Million | +90261.28% |
| 2018-08-31 | $7.44K | -75.42% |
| 2017-08-31 | $30.27K | -- |